Chlamydia is preventable through a combination of barrier protection, regular screening, and partner communication. Because 75% of women and 50% of men with chlamydia show no symptoms at all, prevention depends heavily on proactive steps rather than waiting for warning signs.
Why Prevention Matters More Than You Think
Chlamydia often causes no noticeable symptoms, which means it spreads easily between partners who feel perfectly healthy. The estimated transmission probability from a single unprotected sexual encounter with an infected partner is about 4.5%. That number may sound low, but it adds up quickly over repeated encounters, and because the infection is silent in most cases, many people unknowingly pass it along for weeks or months before getting tested.
Left untreated, chlamydia can cause serious damage. About 10 to 15% of women with untreated chlamydia develop pelvic inflammatory disease, which can permanently scar the fallopian tubes and lead to infertility. For men, untreated infections can cause pain and swelling in the reproductive tract and, in rare cases, affect fertility as well.
Consistent Condom Use
External (male) condoms are the most accessible tool for reducing chlamydia risk during vaginal and anal sex. A study published in the American Journal of Epidemiology found that consistent condom use, meaning every time rather than sometimes, was associated with a 58% reduction in chlamydia and gonorrhea prevalence among people with known exposure to an infected partner. The key word is consistent. Occasional use offered far less protection, dropping to roughly an 18% reduction.
Internal (female) condoms work on the same principle, creating a physical barrier that prevents the bacteria from transferring between mucous membranes. Use a new condom for each act and each type of sex. If you switch from anal to vaginal intercourse, for instance, a fresh condom is necessary to avoid transferring bacteria between sites.
Protection During Oral Sex
Chlamydia can infect the throat through oral sex performed on an infected partner’s genitals or anus. Dental dams, thin sheets of latex or polyurethane placed between the mouth and the vagina or anus, reduce this risk. Place the dam flat over the area before contact begins and keep it in place the entire time. Use a new one each time, and apply water-based or silicone-based lubricant to help prevent tearing. Avoid oil-based products like petroleum jelly or lotion, which break down the material.
For oral sex performed on a penis, a standard external condom provides the same barrier function.
Regular Screening
Because chlamydia so often produces no symptoms, routine testing is one of the most effective prevention strategies at the population level. The CDC recommends annual screening for all sexually active women under 25. Women 25 and older should be screened if they have risk factors like a new partner, multiple partners, a partner with other partners, inconsistent condom use, or a previous STI.
Men who have sex with men should be tested at least annually at all sites of contact (urethra, rectum), regardless of condom use. Those on HIV pre-exposure prophylaxis or with multiple partners should test every 3 to 6 months. For heterosexual men at low risk, routine screening isn’t strongly recommended, though it may be offered in high-prevalence settings like STI clinics or correctional facilities.
Transgender and gender diverse people should follow screening guidelines based on their anatomy. Anyone with a cervix under 25 benefits from annual screening, while those over 25 should be screened based on risk factors.
If you’ve been treated for chlamydia, get retested about 3 months later. Reinfection is common, especially if a partner wasn’t treated simultaneously.
Testing Timing After Exposure
If you think you’ve been exposed, timing matters. Chlamydia tests are most reliable starting about one week after exposure, and waiting two weeks catches nearly all infections. Testing too early can produce a false negative, giving you a clean result while the bacteria are still establishing themselves.
Partner Treatment and Communication
Treating only yourself while your partner remains infected is a recipe for reinfection. Studies show that patients whose partners received treatment through expedited partner therapy, where medication is provided to the partner without requiring a separate doctor visit, were 29% less likely to be reinfected compared to those who simply told their partner to visit a clinic.
If you test positive, notifying recent sexual partners allows them to get tested and treated before spreading the infection further. Many health departments offer anonymous partner notification services if you’re uncomfortable having the conversation yourself. Both partners should avoid sexual contact until treatment is complete.
Mutual Monogamy and Fewer Partners
Being in a mutually monogamous relationship with a partner who has tested negative significantly reduces your risk. The more sexual partners you have, the higher the statistical chance of encountering someone with an undiagnosed infection. This doesn’t mean you need to avoid multiple partners entirely, but combining a smaller number of partners with consistent barrier use and regular testing creates a strong prevention strategy.
Post-Exposure Antibiotics
A newer prevention tool called doxycycline post-exposure prophylaxis, or doxy-PEP, involves taking an antibiotic within 72 hours after unprotected sex. Clinical trials have shown striking results: one French trial found doxy-PEP reduced chlamydia infections by roughly 70%, and a second trial showed up to an 89% reduction. A trial in Kenya showed a more modest effect that didn’t reach statistical significance, suggesting the benefit may vary across populations.
Current CDC guidelines support doxy-PEP for men who have sex with men and transgender women who have had a bacterial STI in the past year. It’s not currently recommended as a blanket strategy for all populations, partly because of concerns about promoting antibiotic resistance with widespread use. If you’re in a higher-risk group, this is worth discussing with a healthcare provider.
Vaccine Development
Unlike HPV or hepatitis B, there is no vaccine available for chlamydia yet. The first phase I clinical trials of a vaccine candidate called CTH522 have been completed, showing the vaccine is safe and triggers an immune response in both men and women. Researchers are now planning a phase II trial that would need around 2,000 participants to determine whether the vaccine actually prevents infections. A widely available chlamydia vaccine is still years away, making behavioral prevention and screening the primary tools for now.